North America Nerve Repair & Regeneration Market Identifying Roles and Objectives In Coming Years till 2028

The North America nerve repair & regeneration market is expected to grow from US$ 3,721.38 million in 2022 to US$ 6,463.51 million by 2028; it is estimated to grow at a CAGR of 9.6% from 2022 to 2028.

๐Ÿ“š ๐ƒ๐จ๐ฐ๐ง๐ฅ๐จ๐š๐ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐๐ƒ๐… ๐‚๐จ๐ฉ๐ฒ@ https://www.businessmarketinsights.com/sample/BMIRE00027759

Rising Prevalence of Age-associated Neurological Disorders among Geriatric Population Boosts North America Nerve Repair & Regeneration Market Growth.

A few neurologic disorders such as neuropathy, Alzheimer’s disease, Parkinson’s disease, and strokes are more common in the geriatric population, and their prevalence is rising with higher life expectancies. According to the WHO, the population aged 60 years will approximately double from 12% in 2015 to 22% by 2050, and mental and neurological disorders among older adults are likely to account for 6.6% of the total disability-adjusted life year (DALYs) for this age group. Also, as per the same source, ~15% of adults aged 60 and over have a mental disorder. Further, the number of people aged 65 years and above affected by Alzheimer’s disease is expected to grow from ~5.8 million to 14 million by 2060 in the US.

๐Ÿ“š๐…๐ฎ๐ฅ๐ฅ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ ๐‹๐ข๐ง๐ค @ https://www.businessmarketinsights.com/reports/north-america-nerve-repair-and-regeneration-market

Moreover, neurological disorders are increasingly becoming a major cause of death across the region. For instance, according to the Centers for Disease Control and Prevention (CDC), Alzheimer’s disease is the fifth leading cause of death in people aged 65 years and above. Therefore, the rising prevalence of age-associated neurological disorders among the geriatric population increases the demand for treatment of nerve repair & regeneration. This factor is propelling the growth of theย North America Nerve Repair & Regeneration Market

๐“๐ก๐ž ๐‹๐ข๐ฌ๐ญ ๐จ๐Ÿ ๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ข๐ž๐ฌ

Axogen Corporation

Boston Scientific Corporation

Integra LifeSciences

Medtronic

Abbott Laboratories

Stryker Corporation

Neuronetics

LivaNova PLC

Baxter

Polyganics BV

Akash Gharge
Author: Akash Gharge

na